Mountcastle David, EVP & Chief Financial Officer, has demonstrated a clear selling bias in recent transactions involving PRVA (Privia Health Group), with no recent purchases recorded. Since December 2025, David has executed multiple sales, including a significant $597,891.61 transaction on December 12, 2025, followed by a series of disposals in February and March 2026. The largest of these recent sales occurred on February 27, 2026, totaling $192,809.85, with additional sales on March 6, 9, 12, 13, and 16, 2026, each ranging between $119,847.55 and $141,320.70. These transactions, alongside smaller awards and derivative transactions marked as "M" (mergers, acquisitions, or other events), suggest a consistent reduction in holdings rather than accumulation.
Overall, David’s trading history reflects a net seller, with total sales exceeding $1.6 million against minimal buy activity ($73,890 lifetime). The concentration in PRVA, with no other companies involved in recent filings, indicates a focused divestment pattern. While some transactions appear routine—such as those tied to derivative events—the repeated sales in early 2026, particularly the cluster in March, underscore a sustained effort to liquidate shares. The absence of any buys during this period further reinforces the directional trend toward reducing exposure to PRVA.
AI-assisted summary